Breast Cancer

Clinical Staff Conference1 August 1965Breast CancerCombined Clinical Staff Conference at the National Institutes of HealthNATHANIEL I. BERLIN, M.D., HOWARD B. ANDERVONT, D.SC., MICHAEL B. SHIMKIN, M.D., B. J. KENNEDY, M.D., EMIL FREI III, M.D.NATHANIEL I. BERLIN, M.D.Search for more papers by this author, HOWARD B. ANDERVONT, D.SC.Search for more papers by this author, MICHAEL B. SHIMKIN, M.D.Search for more papers by this author, B. J. KENNEDY, M.D.Search for more papers by this author, EMIL FREI III, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-63-2-321 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptDr. Nathaniel I. Berlin: This Combined Clinical Staff Conference will be devoted to certain aspects of cancer of the breast. This is the most common malignant tumor in the female. It has been the subject of extensive study by surgeons, radiologists, endocrinologists, internists, and pathologists, and in the laboratory by studies in the mouse.There has been a long-standing campaign, particularly sparked by the American Cancer Society, for self-examination with a view towards early detection. The National Cancer Institute is sponsoring a large-scale program to evaluate mammography in the subscribers to the Health Insurance Plan in New York City.While...References1. SEGIKURIHARA MM: Cancer Mortality for Selected Sites in 24 Countries. No. 2 (1958-1959). Department of Public Health, Tohoku University School of Medicine, Sendai, Japan, March 1962. Google Scholar2. DORNCUTLER HFSJ: Morbidity from Cancer in the United States. Public Health Monograph No. 56. U. S. Dept. of Health, Education, and Welfare, Washington, D. C., U. S. Govt. Printing Office, 1959, 207 pp. Google Scholar3. MERSHEIMERAXTELL WLF: End results in cancer of the female breast. Proceedings of the National Cancer Conference, Fifth, Philadelphia, 1964. To be published. Google Scholar4. CONNECTICUT TUMOR REGISTRY: Unpublished data. Google Scholar5. BITTNER JJ: The mammary tumor milk agent. Ann. N. Y. Acad. Sci. 49: 69, 1947. CrossrefGoogle Scholar6. DMOCHOWSKI L: The milk agent in the origin of mammary tumors in mice. Advances Cancer Res. 1: 103, 1953. CrossrefMedlineGoogle Scholar7. DEOME KB: The role of the mammary tumor virus in mouse mammary noduligenesis and tumorigenesis, in Viruses, Nucleic Acids, and Cancer, The Williams and Wilkins Co., Baltimore, 1963, p. 498. Google Scholar8. BERNNANDI HAS: Recent studies of the hormonal influence in mouse mammary tumorigenesis. Progr. Exp. Tumor Res. 2: 90, 1961. CrossrefMedlineGoogle Scholar9. ANDERVONTDUNN HBTB: Studies of the mammary tumor agent carried by wild house mice. Acta Un. Int. Cancr. 12: 530, 1956. MedlineGoogle Scholar10. DUNNANDERVONT TBHB: Histology of some neoplasma and nonneoplastic lesions found in wild mice maintained under laboratory conditions. J. Nat. Cancer Inst. 31: 873, 1963. MedlineGoogle Scholar11. ROUS P: Concerning the cancer problem. Amer. Sci. 34: 329, 1946. MedlineGoogle Scholar12. ANDREWES CH: The bearing of recent work on the virus theory of cancer. Brit. Med. J. 1: 81, 1950, CrossrefMedlineGoogle Scholar13. OBERLINGGUERIN CM: The role of viruses in the production of cancer. Advances Cancer Res. 2: 353, 1954. CrossrefMedlineGoogle Scholar14. DURAN-REYNALS F: Virus-induced tumors and the virus theory of cancer, in The Physiopathology of Cancer, edited by HOMBURGER, F., Paul B. Hoeber, Inc., New York, 1959, p. 238. Google Scholar15. PITELKABERNNANDIDEOME DRHASKB: On the significance of virus-like particles in mammary tissues of C3Hf mice. J. Nat. Cancer Inst. 33: 867, 1964. CrossrefMedlineGoogle Scholar16. SHIMKIN MB: Cancer of the breast. Some old facts and new prospectives. JAMA 183: 358, 1963. CrossrefMedlineGoogle Scholar17. International Symposium on End Results of Cancer Therapy. National Cancer Institute Monograph 15, 1964, 446 pp. Google Scholar18. BULBROOKHAYWARDSPICERTHOMAS RDJLCCBS: Abnormal excretion of urinary steroids by women with early breast cancer. Lancet 2: 1238, 1962. CrossrefMedlineGoogle Scholar19. BULBROOKTHOMASUTSUNOMIYA RDBSJ: Urinary 11-deoxy-17-oxosteroids in British and Japanese women with reference to the incidence of breast cancer. Nature 201: 189, 1964. CrossrefMedlineGoogle Scholar20. LIECHTYHODGESBURKET RDREJ: Cancer and thyroid function. JAMA 183: 30, 1963. CrossrefMedlineGoogle Scholar21. GERSHON-COHENHERMELBERGER JMBSM: Detection of breast cancer by periodic X-ray examinations, JAMA 176: 1114, 1961. CrossrefMedlineGoogle Scholar22. EGAN RL: Experience with mammography in a tumor institution. Radiology 75: 894, 1960. CrossrefMedlineGoogle Scholar23. Thermography and Its Clinical Applications. Ann. N. Y. Acad. Sci. 121, art. 1, 1964, 304 pp. Google Scholar24. SHIMKIN MB: The numerical method in therapeutic medicine. Public Health Rep. 79: 1, 1964. CrossrefMedlineGoogle Scholar25. SCHNEIDERMAN MA: The proper size of a clinical trial: "Grandma's Strudel" method. J. New Drugs 4: 3, 1964. CrossrefMedlineGoogle Scholar26. Experimental Clinical Cancer Chemotherapy. Second Conference. Cancer Chemother. Rep. No. 16, 1962, 610 pp. Google Scholar27. : Results of studies of the Cooperative Breast Cancer Group 1961-1963. Cancer Chemother. Rep. No. 41, Suppl. 1, 1964, 24 pp. Google Scholar28. LEWISON EF: Prophylactic versus therapeutic castration in the total treatment of breast cancer. Obstet. Gynec. Survey, 17: 769, 1962. CrossrefMedlineGoogle Scholar29. KENNEDYMIELKEFORTUNY BJPWIE: Therapeutic castration versus prophylactic castration in breast cancer. Surg. Gynec. Obstet. 118: 524, 1964. MedlineGoogle Scholar30. SCHINZINGER : Ueber carcinoma mammae (abstract). Zbl. Chir. 16 (29): 28, 1889. Google Scholar31. BEATSON GT: On treatment of inoperable cases of carcinoma of mamma; suggestions for new method of treatment with illustrative cases. Lancet 2: 104, 1896. CrossrefGoogle Scholar32. KENNEDYFORTUNY BJIE: Therapeutic castration in the treatment of advanced breast cancer. Cancer 17: 1197, 1964. CrossrefMedlineGoogle Scholar33. MACDONALD I: Endocrine ablation in disseminated mammary carcinoma. Surg. Gynec. Obstet. 115: 215, 1962. MedlineGoogle Scholar34. NATHANSON IT: Clinical investigative experience with steroid hormones in breast cancer. Cancer 5: 754, 1952. CrossrefMedlineGoogle Scholar35. PEARSONWESTMCLEANLILIPSETT OHCDJPMCMB: Endocrine treatment of metastatic breast cancer. Amer. Surg. 21: 1075, 1955. MedlineGoogle Scholar36. : Androgens and estrogens in the treatment of disseminated mammary carcinoma. Retrospective study of 944 patients. JAMA 172: 1271, 1960. Google Scholar37. KENNEDY BJ: Diethylstilbestrol versus testosterone propionate therapy in advanced breast cancer. Surg. Gynec. Obstet. 120: 1246, 1965. MedlineGoogle Scholar38. : Testosterone propionate therapy in breast cancer. JAMA: 188: 1069, 1964. CrossrefMedlineGoogle Scholar39. PEARSONRAY OHBS: Hypophysectomy in the treatment of metastatic mammary cancer. Amer. J. Surg. 99: 544, 1960. CrossrefMedlineGoogle Scholar40. KENNEDYFRENCH BJL: Hypophysectomy in advanced breast cancer. Unpublished data. Google Scholar41. LANDAUEHRLICHHUGGINS RLENC: Estradiol benzoate and progesterone in advanced human-breast cancer. JAMA 182: 632, 1962. CrossrefGoogle Scholar42. Conference—Comparative clinical and biological effects of alkylating agents. Ann. N. Y. Acad. Sci. 68: 657, 1958. Google Scholar43. GOLDSALVINSHNIDER GLLGBI: A comparative study with three alkylating agents: Mechlorethamine, cyclophosphamide and uracil mustard. Cancer Chemother. Rep. 16: 417, 1962. MedlineGoogle Scholar44. WEISBERGER AS: Direct instillation of nitrogen mustard in the management of malignant effusions. Ann. N. Y. Acad. Sci. 68: 1091, 1958. CrossrefMedlineGoogle Scholar45. ZUBROD CG: The limited usefulness of 5-fluorouracil and 5-fluorodeoxyuridine in the management of patients with adenocarcinoma, in Controversy in Internal Medicine, edited by FINLAND, INGELFINGER, and RELMAN, W. B. Saunders Co., Philadelphia. In press. Google Scholar46. ANSFIELDCURRERI FJAR: Further clinical comparison between 5-fluorouracil and 5-fluorodeoxyuridine. Cancer Chemother. Rep. 32: 101, 1963. MedlineGoogle Scholar47. DAOGRINBERG TLR: Fluorinated pyrimidines in treatment of breast cancer patients with liver metastases. Cancer Chemother. Rep. 27: 71, 1963. MedlineGoogle Scholar48. NEVINNY HB: Comparative study of 5-fluorouracil, 5-fluorodeoxy-uridine, and methotrexate in patients with advanced cancer. Proc. Amer. Ass. Cancer Res. 5: 47, 1964. Google Scholar49. JOHNSONARMSTRONGGORMANBURNETT ISJGMJP: The Vinca alkaloids: A new class of oncolytic agents. Cancer Res. 23: 1390, 1963. MedlineGoogle Scholar50. FREICARBONESHNIDERGOLDCOLSKYFRANZINOKRANTBRENAOWENSHOLLANDCOSTAHALLHOSLEYHORTONTARRSALVIN EPBGLJAMGAHJFGTCHJNLG: A study of vinblastine in the treatment of patients with neoplastic disease. Arch. Intern. Med. In press. Google Scholar51. HOLLAND JF: Eastern solid tumor group. Personal communication. Google Scholar52. SKIPPERSCHNABELWILCOX HEFMWS: Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother. Rep. 35: 1, 1964. MedlineGoogle Scholar53. SURGICAL ADJUVANT STUDIES REPORT 1964. Surgical adjuvant breast study: progress report. Chemotherapy Statistical Unit, Roswell Park Memorial Institute, Buffalo, N. Y. Google Scholar54. BRINDLEYSALVINPOTEELIPOWSKASHNIDERREGELSONCOLSKY COLGKGBBIWJ: Further comparative trial of triethylene thiophosphoramide and mechlorethamine in patients with melanoma and Hodgkin's disease. J. Chronic Dis. 17: 19, 1964. CrossrefMedlineGoogle Scholar55. FREISPURRBRINDLEYSELAWRYHOLLANDRALLWASSERMANHOOGSTRATENSHNIDERMCINTYREMATTHEWSMILLER ECLCOOJFDPLRBBIORLBSP: Clinical studies of dichloromethotrexate. Clin. Pharmacol. Ther. 6: 160, 1965. CrossrefMedlineGoogle Scholar56. FREIREICHKLIMANGAYDOSMANTELFREI EJALANE: Response to repeated platelet transfusion from the same donor. Ann. Intern. Med. 59: 277, 1963. LinkGoogle Scholar57. FREIREICHLEVINWHANGCARBONEBRONSONMORSE EJRHJPPWEE: The function and fate of transfused leukocytes from donors with chronic myelocytic leukemia in leukopenic recipients. Ann. N. Y. Acad. Sci. 113: 1081, 1964. CrossrefMedlineGoogle Scholar58. SCHWARZCOLVINHIMMELSBACHFREI SMCKE: The effect of bacterial suppression and reverse isolation on intensive cancer chemotherapy. Clin. Res. 13: 48, 1965. Google Scholar59. SELAWRYFREI OSE: Prolongation of remission in acute lymphocytic leukemia by alteration in dose schedule and route of administration of methotrexate. Clin. Res. 12: 231, 1964. Google Scholar60. GREENSPAN EM: Combinations of methotrexate, thioTEPA, and 5-fluorouracil in advanced breast carcinoma. Proc. Amer. Ass. Cancer Res. 5: 23, 1964. Google Scholar61. KAYHOE DE: Personal communication. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: This is an edited transcription of a combined clinical staff conference at the Clinical Center, Bethesda, Md., by the National Cancer Institute, National Institutes of Health, Public Health Service, United States Department of Health, Education, and Welfare.Requests for reprints should be addressed to Nathaniel I. Berlin, M.D., Clinical Director, National Cancer Institute, Bldg. 10, Room 4-B-17 National Institutes of Health, Bethesda, Md. 20014. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byCancer in the male breastA Multidisciplined Approach for the Management of Metastatic Breast CancerPrednisone and PrednisoloneDrug Therapy for Neoplastic Disease in AdultsProphylactic oophorectomy in breast cancer therapyThe Therapy of Advanced Female Breast Cancer: An Appraisal of the Present Status and Problems 1 August 1965Volume 63, Issue 2Page: 321-341KeywordsBreast cancerEndocrine therapyMalignant tumorsMammographyMedical servicesPathologistsPrevention, policy, and public healthRadiologistsResearch laboratoriesSurgeons Issue Published: 1 August 1965 PDF downloadLoading ...